Ascendis swings for an $86M IPO; Zymeworks banks $4M for bispecific antibody R&D;

@FierceBiotech: Juno banks $265M in an IPO, pushing the next big thing in oncology. Story | Follow @FierceBiotech

@JohnCFierce: You want to start an argument? Walk into a room full of neuroscientists and shout 'amyloid beta.' | Follow @JohnCFierce

@DamianFierce: $MRK + $CBST tick-tock shows Frazier wanted $HSP decision contingency and Bonney talked him out of it. More | Follow @DamianFierce

> Canadian biotech Zymeworks banked a $4 million investment from Fonds de solidarité FTQ, a Québec-based development outfit. More

> Denmark's Ascendis Pharma filed to raise as much as $86 million in an IPO, cash that would support the development of a proprietary hydrogel made of prodrug linkers that seek out targeted molecules in the body and then release their therapeutic payload. F-1

> Venrock Associates Partner Bryan Roberts talks to The Wall Street Journal about how his firm pulled off an impressive 6 exits in 2014. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA warns against inappropriate use of fetal ultrasound imaging and heartbeat monitoring. Article | Follow @FierceMedDev

@EmilyWFierce: Myriad Genetics stymied in BRCA breast cancer test patent battle. Story | Follow @EmilyWFierce

> Private equity firm backs Sonoma Orthopedic with $12M to get ankle implant to market. More

> Small cap Cerus spikes on back-to-back Intercept approvals by FDA. News

> FDA outlines UDI implementation plans for 2015. More

Pharma News

@FiercePharma: Have you read our latest report? Not to be missed: The top 10 patent losses of 2015. Report | Follow @FiercePharma

@CarlyHFierce: ICYME: Flush-with-cash Shire revisits deal for NPS Pharma. More | Follow @CarlyHFierce

> Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster PhIII data. Story

> China promises faster drug approvals, equal treatment for U.S. companies. Article

> Salix investors pushing for sale once supply issues wrap. News

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.